Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

248 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
CCSVI: hope, hype or snake oil?
Oger J, Alkhawajah M. Oger J, et al. Can J Neurol Sci. 2010 Nov;37(6):716. Can J Neurol Sci. 2010. PMID: 21059529 No abstract available.
Where are we going with drugs to treat MS? Will cost continue to increase?
Oger J, AlKhawajah M. Oger J, et al. Can J Neurol Sci. 2010 May;37(3):305-8. doi: 10.1017/s0317167100010167. Can J Neurol Sci. 2010. PMID: 20481262 English, French. No abstract available.
Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients.
Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger JD, Petkau J. Tremlett H, et al. Neurology. 2006 Oct 10;67(7):1291-3. doi: 10.1212/01.wnl.0000238515.27055.62. Neurology. 2006. PMID: 17030771 Clinical Trial.
A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
Lawrence N, Oger J, Aziz T, Palace J, Vincent A. Lawrence N, et al. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1236-9. doi: 10.1136/jnnp.74.9.1236. J Neurol Neurosurg Psychiatry. 2003. PMID: 12933925 Free PMC article. Clinical Trial.
Potassium channel antibodies in two patients with reversible limbic encephalitis.
Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, Vincent A. Buckley C, et al. Ann Neurol. 2001 Jul;50(1):73-8. doi: 10.1002/ana.1097. Ann Neurol. 2001. PMID: 11456313
Genetic susceptibility to MS: a second stage analysis in Canadian MS families.
Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C, Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P, Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC. Dyment DA, et al. Neurogenetics. 2001 Jul;3(3):145-51. doi: 10.1007/s100480100113. Neurogenetics. 2001. PMID: 11523565 Clinical Trial.
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Lee I, Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJG, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Minisman G, Sonett JR, Wolfe GI; MGTX study group. Lee I, et al. Among authors: Oger J. Neurology. 2020 Jul 1:10.1212/WNL.0000000000010031. doi: 10.1212/WNL.0000000000010031. Online ahead of print. Neurology. 2020. PMID: 32611638
Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.
Schwehr NA, Kuntz KM, Enns EA, Shippee ND, Kingwell E, Tremlett H, Carpenter AF, Butler M; BeAMS Study group. Schwehr NA, et al. Drugs Aging. 2020 Mar;37(3):225-235. doi: 10.1007/s40266-019-00741-1. Drugs Aging. 2020. PMID: 31916231
Multiple sclerosis: effect of beta interferon treatment on survival.
Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H. Kingwell E, et al. Among authors: Oger J. Brain. 2019 May 1;142(5):1324-1333. doi: 10.1093/brain/awz055. Brain. 2019. PMID: 30883636 Free article. Clinical Trial.
248 results
Jump to page
Feedback